We discuss a black swan event. A sobering reminder of the limitations of surrogate endpoints @mtmdphd @Rfonsi1 @BldCancerDoc
Thread
1/
1. Double edge sword, or
2. Wolf in sheep’s clothing
- Surrogate endpoints don’t mean real clinical benefit has occurred.
- Overall survival is an aggregate endpoint. Requires not just efficacy BUT also safety.
- RCTs are the only to be sure of true clinical benefit
@myelomaMD @MayoMyeloma @NorthTxMSG @MyelomaTeacher @Mohty_EBMT
The last pint should read “RCTs are the only way to be sure of true clinical benefit"